No abstract available.
Psychopharmacology*

No abstract available.
Psychopharmacology*

No abstract available.
Neurosciences* ; Psychopharmacology*

No abstract available.
Adolescent* ; Child* ; Humans ; Psychopharmacology*

Improvement of psychopharmacology resulted in changes in therapeutic target for patients with schizophrenia. Although the control of psychotic symptoms are considered to be the primary goal of treatment in schizophrenia, in recent years, functional recovery and improvement of quality of life (QoL) has been highlighted as the new therapeutic target. In this article, we reviewed the definition, assessment tools, and recent studies which have been done in Korea. QoL is complex and heterogenous concept, thus there have been no gold-standard measures for QoL. Standardization of assessment tools for Koreans has set the infrastructure for QoL researches in patients with schizophrenia. More researches are needed in this area, and it could provide information for the development of psychosocial program and systemic support for improving schizophrenic patient's QoL.
Humans ; Korea ; Psychopharmacology ; Quality of Life* ; Schizophrenia*

Recently, the Korean College of Neuropsychopharmacolgy (KCNP) published an English language journal "Clinical Psychopharmacology and Neuroscience" for the purpose of international communications in the area of neuropsychopharmacology and related biological psychiatry. Historically, it is the first foreign language journal published in the Korean psychiatric society. This is writing to the background of publishing an English language journal in the perspectives of the limitations of Korean language journal and the international communications with researchers all over the world. The major concerns in publishing an English language journal are discussed. The future plan of continuously publishing "Clinical Psychopharmacology and Neuroscience" and some suggestions for the researchers who are going to submit manuscripts and to read this journal are described. We hope this is helpful for the publication of English language journal planning in the editorial committee of the Korean Neuropsychiatric Association.
Biological Psychiatry ; Hope ; Psychopharmacology* ; Publications* ; Writing

OBJECTIVE: The objectives are to deliver clinicians and researchers in academia the history, ethics, current principles, guidelines and issues of research in child and adolescent psychopharmacology and to identify challenges facing professionals in the field. METHODS: Children as research subjects were exploited and abused until the middle of 20th century. The response to the conduct of unethical research lead to the overprotection of human subjects in biomedical and behavioral research. In the 1990s, increased spending and the introduction of pediatric exclusivity lead to a large increase in pediatric psychopharmacologic research. Despite the increased number of research, concerns exist about methods and bioethics for making new medications available for use in child and adolescent psychiatric disorders. Through literature review and personal experience, concerns and issues surrounding the research in child and adolescent psychopharmacology were discussed. CONCLUSION: To ensure early access of new drugs for treating psychiatric disorders in children and adolescents, we must strengthen our ability to self-assess in the field of research, be familiar with bioethics and be able to address the challenges posed by the restrictive environment governing child and adolescent psychopharmacology research.
Adolescent* ; Behavioral Research ; Bioethics ; Child* ; Ethics ; Humans ; Psychopharmacology* ; Research Subjects

After publishing 2001 version of the Korean Medication Algorithm for Schizophrenia, the strategy of pharmacologic treatment for schizophrenia has been altered with the rapid advancement in the area of psychopharmacology. Currently, the feasibility of this algorithm has been evaluated. Guidelines require updating when significant new evidence appears. Recently, several guidelines of the treatment of schizophrenia including the APA practice guideline, the Expert Consensus Guideline Series and the Texas Medication Algorithm Project (TMAP) Antipsychotic Algorithm for Schizophrenia were revised. In this review, the authors briefly discussed the problems and limitations of the Korean Medication Algorithm for Schizophrenia and presented the direction of future revision on the model of above-mentioned guidelines.
Consensus ; Drug Therapy ; Methods* ; Practice Guidelines as Topic ; Psychopharmacology ; Schizophrenia* ; Texas

In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
Complement System Proteins ; Depression ; Depressive Disorder* ; Psychiatry ; Psychopharmacology

The rapid development of psychotropic drugs and great advancement in psychopharmacology during the past recent years has altered the strategy of pharmacotherapy for major psychiatric disorders, and in turn, an active development of various clinical practice guidelines or algorithm has taken place. However, there could be problems with applying the foreign guidelines directly to our clinical situation, due to the differences in racial characteristics, socioeconomic conditions, government policy, and clinical practices. In addition, the changes of circumstances outside of clinical situation in Korea may distort clinical practices and may go even against the trend of recent psychopharmacology. As a solution to such problems, Korean Medication Algorithm Project for Major Psychiatric Disorders (KMAP) was launched with the support from the Korean Society of Psychopharmacology and Korean Academy of Schizophrenia. However, since clinical practice guidelines and algorithms contain not only the advantages, but also disadvantages and risks, sufficient consideration must precede the development of algorithms. Hence, this review provides a discussion on the definition of clinical guideline and its limitation, its advantages and disadvantages, and the need for the development of clinical guideline in psychiatric field. Also, developing source, dissemination and implementation of clinical practice guidelines were also discussed. We hope that this review can make the purpose of KMAP clear and elicit the productive criticism on Korean algorithm.
Drug Therapy ; Hope ; Korea ; Psychopharmacology ; Psychotropic Drugs ; Schizophrenia